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Intratumoural expression of deoxycytidylate deaminase or
ribonuceotide reductase subunit M1 expression are not related
to survival in patients with resected pancreatic cancer given
adjuvant chemotherapy
N. O. Elander1, K. Aughton1, P. Ghaneh1, J. P. Neoptolemos1, D. H. Palmer1, T. F. Cox1, F. Campbell1, E. Costello1, C. M. Halloran1,
J. R. Mackey2, A. G. Scarfe2, J. W. Valle 3, A. C. McDonald4, R. Carter5, N. C. Tebbutt6, D. Goldstein7, J. Shannon8, C. Dervenis9,
B. Glimelius10, M. Deakin11, R. M. Charnley12, A. Anthoney13, M. M. Lerch14, J. Mayerle15, A. Oláh16, M. W. Büchler17 and
W. Greenhalf1 for the European Study Group for Pancreatic Cancer
BACKGROUND: Deoxycytidylate deaminase (DCTD) and ribonucleotide reductase subunit M1 (RRM1) are potential prognostic and
predictive biomarkers for pyrimidine-based chemotherapy in pancreatic adenocarcinoma.
METHODS: Immunohistochemical staining of DCTD and RRM1 was performed on tissue microarrays representing tumour samples
from 303 patients in European Study Group for Pancreatic Cancer (ESPAC)-randomised adjuvant trials following pancreatic
resection, 272 of whom had received gemcitabine or 5-fluorouracil with folinic acid in ESPAC-3(v2), and 31 patients from the
combined ESPAC-3(v1) and ESPAC-1 post-operative pure observational groups.
RESULTS: Neither log-rank testing on dichotomised strata or Cox proportional hazard regression showed any relationship of DCTD
or RRM1 expression levels to survival overall or by treatment group.
CONCLUSIONS: Expression of either DCTD or RRM1 was not prognostic or predictive in patients with pancreatic adenocarcinoma
who had had post-operative chemotherapy with either gemcitabine or 5-fluorouracil with folinic acid.
British Journal of Cancer (2018) 118:1084–1088; https://doi.org/10.1038/s41416-018-0005-1
INTRODUCTION
Ductal adenocarcinoma of the pancreas is among the five leading
causes of cancer-related death worldwide.1,2 Post-operative
chemotherapy with pyrimidine monotherapy or combination
regimens is now the standard of care following resection.3–9
Biomarkers that could select patients for specific types of
chemotherapy to improve survival even further would be of
significant clinical value in this disease.
The biological response to 5-fluorouracil and gemcitabine is
regulated by a series of proteins involved in the transmembrane
uptake and intracellular metabolism of pyrimidines, and several of
these are potential biomarkers for pyrimidine-based chemother-
apy.2,10 Recently, we have reported that high expression of human
equilibrative nucleotide transporter (hENT)-1 was associated with
improved overall survival in patients randomised to gemcitabine
in the ESPAC-3(v2) adjuvant trial, but not in those who had
received 5-fluorouracil with folinic acid.11
Deoxycytidylate deaminase (DCTD) converts phosphorylated
gemcitabine into its inactive metabolite12 and ribonucleotide
reductase subunit 1 (RRM1) is a key target of the bioactive
gemcitabine metabolite.13
In the present study, we assessed whether intratumoural
expression of DCTD or RRM1 may be prognostic for patients with
pancreatic adenocarcinoma who had had post-operative adjuvant
chemotherapy with either gemcitabine or 5-fluoruracil with folinic
acid in the European Study Group for Pancreatic Cancer (ESPAC)-3
(v2)-randomised adjuvant trial,4 and in patients from the
combined ESPAC-1 and ESPAC-3(v1) post-operative pure observa-
tional groups.14
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MATERIALS AND METHODS
Study design and tissue microarray manufacture
The translational ESPAC-T studies received ethical committee
approval for characterisation of tumour markers for chemotherapy
from the Liverpool (Adult) Research Ethics Committee (07/H1005/
87). The design of the ESPAC-1 and ESPAC-3(v2) trials, and the
generation of tissue microarrays (TMAs), have been described
previously.3,4,6,11,14
Immunohistochemistry on tissue microarray sections
The primary antibodies were validated in accordance with the
principles stated by the ESPAC Steering Committee
Table 1. Summary of numbers and outcomes in the respective arms
of the original trials
Trial Arm n mOS (95% CI) Reference
ESPAC- 3(v2) GEM 537 23.6 (21.4–26.4) 4
ESPAC-3(v2) 5FU 551 23.0 (21.1–25.0)
Pooled ESPAC-1/ESPAC-3(v1) OBS 225 16.8 (14.3–19.2) 14
GEM gemcitabine, 5FU 5-fluorouracil with folinic acid, OBS observational
arm, mOS median overall survival, 95% CI 95% confidence interval
A B
DC
E F
HG
RRM1
DCTD
Fig. 1 DCTD and RRM1 immunhistochemistry scoring. Representative images of DCTD negative (a), weak (b), moderate (c), and strong (d)
expressing tumours, and RRM1 negative (e), weak (f), moderate (g) and strong (h) expressing tumours, respectively
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(Supplementary Materials and Methods, antibodies were vali-
dated according to Good Clinical Practice Guidelines as shown
in supplementary figures 1 to 4). TMA blocks of core biopsies
were cut in 3 µm sections and placed on Superfrost Ultra Plus®
slides (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Deparaffinisation and antigen retrieval were performed with
the PT-Link® (Dako, Glostrup, Denmark) system and the pH 9.0
target retrieval buffer. All buffers and reagents were provided in
the EnVision™ kit (Dako): slides were washed in Tris-buffered
saline with 0.05% Tween-20 (TBS-T) before treated with
peroxidase blocker for 10 min. Following TBS-T washes, samples
were incubated with primary antibody diluted 1:200 (anti-DCTD,
60 min incubation time) or 1:50 (anti-RRM1, 30 min incubation
time), followed by secondary Horse Radish Peroxidase Horse
Radish Peroxidase (HRP)-conjugated antibody, repeated TBS-T
washes, and diamensobenzidine according to supplier’s recom-
mendation. Slides were washed in TBS-T and distilled water and
counterstained in Hematoxylin Gills III and dehydrated via a
series of ethanol gradients and fresh Xylen, before being
mounted under cover glasses.
Scoring
The tumour cell compartments of all samples were scored by
one experienced pancreas pathologist (F.C.) and one trained
assistant (N.O.E.) according to a 0–3 system (0 = no staining, 1
= weak, 2=moderate, 3 = strong staining) both being
blinded to patient identity and clinical data. If staining
intensity within the core was not consistent, the most
commonly observed pattern was scored. Any disagreement
was resolved through discussion and a consensus decision.
Each patient was given a single scoring grade equal to the
mean over cores, rounded to the nearest integer. Antibodies
were validated according to Good Clinical Practice Guidelines
as shown in supplementary figures 1 to 4 where the
supplementary material is referenced.
Statistics
Survival from date of randomisation was analysed using
Kaplan–Meier curves, with differences between groups assessed
using the log-rank test. Univariate and multivariate analyses were
carried out using Cox proportional hazards. Presuming a
symmetric 0.5:0.5 ratio between ‘high’ vs. ‘low’ would mean that
a total of 66 events are required to detect a Hazard Ratio (HR) of
2.0 with 0.05 statistical significance level and an 80% power. All
analyses were carried out using SAS version 9.3 software (SAS
Institute, Cary, NC).
RESULTS
Patients and scoring of DCTD and RRM1
In total, 303 patients had providedwritten informed consent for use of
their tissue for research and had tissue available for immunohisto-
chemical staining, of whom 272 had had chemotherapy in the ESPAC-
3(v2)-randomised adjuvant trial,4 and 31 had pure observation
following resection from the combined ESPAC-1/ESPAC-3(v1)-rando-
mised studies.14 Clinical and pathological characteristics of the original
patient populations have been described earlier.3,4,6,11 A summary of
the original trial populations and outcomes are displayed in Table 1.
Scoring and Cox PH regression analyses of DCTD and RRM1
Representative images of scoring grades 0 (negative), 1 (weak), 2
(moderate), and 3 (strong) of DCTD and RRM1 are displayed in
Fig. 1a–h, and the distribution of scores in Supplementary Table 1.
Cox PH regression analysis did not reveal any significant
association with overall survival of mean DCTD expression level
in the 5-fluorouracil with folinic acid group (HR 1.15, p= 0.33),
gemcitabine group (HR 0.93, p= 0.65), or the observational group
(HR 1.14, p= 0.64). Analysis of mean RRM1 expression levels also
did not reveal any significant association with overall survival in
the 5-fluorouracil with folinic acid arm (HR 1.14, p= 0.42), the
gemcitabine arm (HR 0.96, p= 0.79) or the observational
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Fig. 2 Kaplan–Meier survival curves of patient strata dichotomised on DCTD (a, b) and RRM1 (c, d) expression status (negative/weak= 0/1,
moderate/strong= 2/3). 5-FU patients treated with 5-fluorouracil and folinic acid, GEM patients treated with gemcitabine, y axis proportion of
patients being alive, xaxis weeks from randomisation. p values for log-rank χ2 analyses are given in the respective graph
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subgroup (HR 1.97, p= 0.20). Since univariate regression analysis
did not reveal any significant association with overall survival for
either DCTD or RRM1 expression, further multivariate analyses for
other prognostic markers were not performed.
Median overall survival and log-rank tests of DCTD-low vs. DCTD-
high expression and RRM-low vs. RRM1-high expression
Patients were grouped according to DCTD and RRM1 expression
into low (scoring 0–1) and high (scoring 2–3) expression
(Kaplan–Meier curves in Fig. 2a–d). Log-rank testing did not reveal
any significant differences in any of the treatment arms (X2LD p
values given in Fig. 2a–d). An alternative splitting was performed,
where patients were categorised as negative (score= 0) vs.
positive (scores 1–3) expression, without revealing any significant
differences in any of the studied subgroups (data not shown). For
the observation subgroup, Kaplan–Meier curves and log-rank
testing were not performed due to the low number of patients in
the respective stratum.
DISCUSSION
Intratumoural DCTD and RRM1 protein expression was analysed in
patient samples from the ESPAC-3(v2) trial with patients
randomised to either gemcitabine or 5-fluorourcal with folinic
acid4 following pancreatic resection, and also in patients from the
ESPAC-1 and ESPAC-3(v1) trials not receiving post-operative
chemotherapy. None of the analysed biomarkers were associated
with overall survival. To the best of our knowledge, we are the first
group to publish data on DCTD protein expression in pancreatic
cancer specimens. In line with our results, Ashida et al.15
investigated DCTD messenger RNA (mRNA) expression in tissue
samples from 35 patients with advanced pancreatic cancer before
starting gemcitabine treatment, without observing any significant
association with overall survival.
In a multi-centre study from France, Marechal et al.16 found
that intratumoural RRM1 protein expression was not signifi-
cantly associated with survival time in tissue from 208 patients
with pancreatic adenocarcinoma cancer who had been given
post-operative gemcitabine monotherapy. In a study from
Cleveland, Xie et al.17 found that intratumoural RRM1 mRNA
expression did not have significant prognostic value in 122
patients who had had resection for pancreatic adenocarci-
noma, whereas low RRM1 expression was associated with
longer overall survival in the 44 patients who had received
adjuvant gemcitabine. In contrast, high RRM1 expression was
associated with longer overall survival in the 35 patients who
had received non-gemcitabine adjuvant therapy. In a study
from Japan, Nakagawa et al.18 found that RRM1 intratumoural
protein expression was an independent prognostic marker in
109 patients who had resection and post-operative gemcita-
bine therapy. The conflicting nature of previous reports may
reflect different methodologies (mRNA and protein expression
analyses, the latter being performed with different protocols
and antibodies) and biases from the retrospective nature of
these studies, as well as genetic heterogeneity for predictive 5-
fluorouracil-related toxicity.19 These biases are largely over-
come by studying patients from prospective multi-centre
randomised trials, as in our study. Notably, the proportion of
RRM1-high in our population was comparable with the
proportions of RRM1-high observed in the aforementioned
studies.16–18
In conclusion, intratumoural RRM1 and DCTD protein expression
levels in patient samples from prospective randomised controlled
trials involving adjuvant therapy with either gemcitabine or 5-
fluorouracil with folinic acid have shown no association with
survival when analysed in isolation of other markers, thus by
themselves they are not suitable prognostic or predictive
biomarker candidates.
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